-
The FDA has approved the first once-daily, quaternary ammonium, anticholinergic bronchodilator for the treatment of chronic obstructive pulmonary disease.
-
As determined by process-of-care measurement, adverse event occurrence, and patient satisfaction, quality of care is compromised by infection control procedures.
-
For unvaccinated or high-risk vaccinated patients during the influenza season, empirical oseltamivir treatment is cost-effective. For other patients, rapid diagnostic testing followed by treatment with oseltamivir is cost-effective. Empirical amantadine treatment offers a low-cost alternative if patients cannot afford oseltamivir.
-
There is an association between long-distance air flights and venous thromboembolism, but the role of traditional risk factors and prophylactic measures requires more study.
-
Sleep and headache have a long and complex relationship. Morning (or awakening) headache has been linked to sleep disorders, especially obstructive sleep apnea syndrome, but this association is controversial.
-
It appears safe to conclude that patients with mild-to-moderate angina can be safely managed with continued medical therapy, but percutaneous coronary intervention is certainly indicated and appropriate if anginal symptoms are not controlled by maximum, aggressive medical management.
-
-
Did the ephedra ban mark a new era of dietary supplement regulation at the FDA? Altern Med Alert 224;7(8):S1-S2.
-
Greenfield RH. Manipulative therapy for shoulder pain. Altern Med Alert 2004;7(12):144.
-
